-
01
-
Acharya JN, Satischandra P, Asha T, Shankar SK. Lafora's disease in South India: a clinical, electrophysiologic and pathologic study. Epilepsia 1993;34:476-87.
PMID 8389290
-
02
-
Afrantou T, Lagoudaki R, Papadopoulos T, et al. Novel frameshift variant of NHLRC1 gene in compound heterozygosity in an adult Greek patient with Lafora disease. Seizure 2021;86:49-51.
PMID 33540374
-
03
-
Altindag E, Kara B, Baykan B, et al. MR spectroscopy findings in Lafora disease. J Neuroimaging 2009;19(4):359-65.
PMID 19040628
-
04
-
Andermann F, Berkovic SF, Carpenter S, Andermann E. The Ramsay Hunt syndrome is no longer a useful diagnostic category. Mov Disord 1989;4:14-7.
PMID 2494436
-
05
-
Berg AT, Berkovic SF, Brodie MJ, et al. Revised terminology and concepts for organization of seizures and epilepsies: report of the ILAE Commission on Classification and Terminology, 2005-2009. Epilepsia 2010;51:676-85.
PMID 20196795
-
06
-
Berkovic SF, Andermann F, Carpenter S, Wolfe LS. Progressive myoclonus epilepsies: specific causes and diagnosis. N Engl J Med 1986;315:296-305.
PMID 3088452
-
07
-
Berkovic SF, So NK, Andermann F. Progressive myoclonus epilepsies: clinical and neurophysiological diagnosis. J Clin Neurophysiol 1991;8:261-74.
PMID 1918332
-
08
-
Berthier A, Paya M, Garcia-Cabrero AM, et al. Pharmacological interventions to ameliorate neuropathological symptoms in a mouse model of Lafora disease. Mol Neurobiol 2016;53(2):1296-309.
PMID 25627694
-
09
-
Boccella P, Striano P, Zara F, et al. Bioptically demonstrated Lafora disease without EPM2A mutation: a clinical and neurophysiological study of two sisters. Clin Neurol Neurosurg 2003;106:55-9.
PMID 14643920
-
10
-
Brewer MK, Grossman TR, McKnight TR, Goldberg YP, Landy H, Gentry MS. The 4th International Lafora Epilepsy Workshop: Shifting paradigms, paths to treatment, and hope for patients. Epilepsy Behav 2019;90:284-6.
PMID 30528121
-
11
-
Brewer MK, Putaux JL, Rondon A, et al. Polyglucosan body structure in Lafora disease. Carbohydr Polym 2020;240:116260.
PMID 32475552
-
12
-
Cardinali S, Canafoglia L, Bertoli S, et al. A pilot study of a ketogenic diet in patients with Lafora body disease. Epilepsy Res 2006;69:129-34.
PMID 16504479
-
13
-
Carpenter S, Karpati G. Sweat gland duct cells in Lafora disease: diagnosis by skin biopsy. Neurology 1981;31:1564-8.
PMID 6796905
-
14
-
Chan EM, Andrade DM, Franceschetti S, Minassian B. Progressive myoclonus epilepsies: EPM1, EPM2A, EPM2B. Adv Neurol 2005;95:47-57.
PMID 15508913
-
15
-
Commission on Classification and Terminology of the International League Against Epilepsy. Proposal for revised classification of epilepsies and epileptic syndromes. Epilepsia 1989;30(4):389-99.
PMID 2502382
-
16
-
d’Orsi G, Lalla A, Palumbo O, et al. The presenting symptoms of Lafora disease: an electroclinical and genetic study in five Apulian (Southern Italy) families. Seizure 2020;83:145-53.**
PMID 33152654
-
17
-
Dubey D, Ganesh S. Modulation of functional properties of laforin phosphatase by alternative splicing reveals a novel mechanism for the EPM2A gene in Lafora progressive myoclonus epilepsy. Hum Mol Genet 2008;17:3010-20.
PMID 18617530
-
18
-
Dubey D, Parihar R, Ganesh S. Identification and characterization of novel splice variants of the human EPM2A gene mutated in Lafora progressive myoclonus epilepsy. Genomics 2012;99:36-43.
PMID 22036712
-
19
-
Duran J, Gruart A, Garcia-Rocha M, Delgado-Garcia JM, Guinovart JJ. Glycogen accumulation underlies neurodegeneration and autophagy impairment in Lafora disease. Hum Mol Genet 2014;23(12):3147-56.
PMID 24452334
-
20
-
Elliot EJ, Talbot IC, Pye IF, Hodges S, Swift PG, Tanner MS. Lafora disease: a progressive myoclonus epilepsy. J Paediatr Child Health 1992;28:455-8.
PMID 1466943
-
21
-
Engel J Jr; International League Against Epilepsy (ILAE). A proposed diagnostic scheme for people with epileptic seizures and with epilepsy: report of the ILAE Task Force on Classification and Terminology. Epilepsia 2001;42(6):796-803.
PMID 11422340
-
22
-
Ferlazzo E, Canafoglia L, Michelucci R, et al. Mild Lafora disease: clinical, neurophysiologic, and genetic findings. Epilepsia 2014;55(12):e129-33.
PMID 25270369
-
23
-
Fu Y, Zhou C, Song R, et al. A novel compound heterozygous EPM2A mutation in a Chinese boy with Lafora disease. Neurol Sci 2020;41(8):2267-70.
PMID 32342326
-
24
-
Ganesh S, Delgado-Escueta AV, Suzuki T, et al. Genotype-phenotype correlations for EPM2A mutations in Lafora's progressive myoclonus epilepsy: exon 1 mutations associate with an early-onset cognitive deficit subphenotype. Hum Mol Genet 2002;11(11):1263-71.
PMID 12019207
-
25
-
Ganesh S, Puri R, Singh S, Mittal S, Dubey D. Recent advances in the molecular basis of Lafora's progressive myoclonus epilepsy. J Hum Genet 2006;51(1):1-8.
PMID 16311711
-
26
-
Garcia-Cabrero AM, Marinas A, Guerrero R, de Córdoba SR, Serratosa JM, Sánchez MP. Laforin and malin deletions in mice produce similar neurologic impairments. J Neuropathol Exp Neurol 2012;71(5):413-21.
PMID 22487859
-
27
-
Genton P. Lafora's disease (EPM2). Rev Neurol (Paris) 2007;163:47-53.
PMID 17304172
-
28
-
Genton P, Malafosse A, Moulard B, et al. Progressive myoclonus epilepsies. In: Roger J, Bureau M, Dravet C, Genton P, Tassinari CA, Wolf P, editors. Epileptic syndromes in infancy, childhood and adolescence, 4th edition. Montrouge, France: John Libbey Eurotext, 2005:441-65.
-
29
-
Gentry MS, Afawi Z, Armstrong DD et al. The 5th International Lafora Epilepsy Workshop: basic science elucidating therapeutic options and preparing for therapies in the clinic. Epilepsy Behav 2020;103(Pt A):106839.
PMID 31932179
-
30
-
Giraldez BG, Serratosa JM. Lafora disease. In: Panayiotopoulos CP, editor. Atlas of epilepsies. London: Springer; 2010:1231-4.
-
31
-
Goldsmith D, Minassian BA. Efficacy and tolerability of perampanel in ten patients with Lafora disease. Epilepsy Behav 2016;62:132-5.
PMID 27459034
-
32
-
Gomez-Abad C, Gomez-Garre P, Gutierrez-Delicado E, et al. Lafora disease due to EPM2B mutations: a clinical and genetic study. Neurology 2005;64(6):982-6.
PMID 15781812
-
33
-
Gomez-Garre P, Gutierrez-Delicado E, Gomez-Abad C, et al. Hepatic disease as the first manifestation of progressive myoclonus epilepsy of Lafora. Neurology 2007;68:1369-73.
PMID 17452581
-
34
-
Halliday AM. The clinical incidence of myoclonus. In: Williams D, editor. Modern trends in neurology. Vol. 4. London: Butterworths, 1967:69-105.
-
35
-
Ianzano L, Zhang J, Chan EM, et al. Lafora progressive myoclonus epilepsy mutation database-EPM2A and NHLRC1 (EMP2B) genes. Hum Mutat 2005;26(4):397.
PMID 16134145
-
37
-
Kaufman MA, Dwork AJ, Willson NJ, John S, Liu JD. Late-onset Lafora's disease with typical intraneuronal inclusions. Neurology 1993;43(6):1246-8.
PMID 8170576
-
38
-
Kecmanovic M, Keckarevic-Markovic M, Keckarevic D, Stevanovic G, Jovic N, Romac S. Genetics of Lafora progressive myoclonic epilepsy: current perspectives. Appl Clin Genet 2016;9:49-53.
PMID 27194917
-
39
-
Lafora GR. Uber das Vorkommen amyloider Korperchen im Innern der Ganglienzellen: zugleich en Beitrag zum Studium der amyloiden Substanz im Nervensystem. Virchows Arch Pathol Anat Physiol Klin Med 1911;205:295-303.
-
40
-
Lafora GR, Glueck B. Beitrag zur Histopathologie der myoklonischen Epilepsie. Z Gesamte Neurol Psychiatr 1911;6:1-14.
-
41
-
Lesca G, Boutry-Kryza N, de Toffol B, et al. Novel mutations in EPM2A and NHLRC1 widen the spectrum of Lafora disease. Epilepsia 2010;51(9):1691-8.
PMID 20738377
-
42
-
Lohi H, Turnbull J, Zhao XC, et al. Genetic diagnosis in Lafora disease: genotype-phenotype correlations and diagnostic pitfalls. Neurology 2007;68:996-1001.
PMID 17389303
-
43
-
Mikati MA, Tabbara F. Managing Lafora body disease with vagal nerve stimulation. Epileptic Disord 2017;19(1):82-6.
PMID 28238966
-
44
-
Mittal S, Dubey D, Yamakawa K, Ganesh S. Lafora disease proteins malin and laforin are recruited to aggresomes in response to proteasomal impairment. Hum Mol Genet 2007;16:753-62.
PMID 17337485
-
45
-
Monaghan TS, Delanty N. Lafora disease: epidemiology, pathophysiology and management. CNS Drugs 2010;24(7):549-61.
PMID 20527995
-
46
-
Muccioli L, Farolfi A, Pondrelli F, et al. FDG-PET assessment and metabolic patterns in Lafora disease. Eur J Nucl Med Mol Imaging 2019. [Epub ahead of print]
PMID 31858178
-
47
-
Nitschke F, Ahonen SJ, Nitschke S, Mitra S, Minassian BA. Lafora disease - from pathogenesis to treatment strategies. Nat Rev Neurol 2018;14(10):606-17.
PMID 30143794
-
48
-
Panayiotopoulos CP. Diseases frequently associated with epileptic seizures. In: Panayiotopoulos CP, editor. A Clinical Guide to Epileptic Syndromes and Their Treatment. Revised 2nd edition. London: Springer, 2010:533-63.
-
49
-
Parihar R, Rai A, Ganesh S. Lafora disease: from genotype to phenotype. J Genet 2018;97(3):611-24.
PMID 30027899
-
50
-
Pederson BA, Turnbull J, Epp JR, et al. Inhibiting glycogen synthesis prevents Lafora disease in a mouse model. Ann Neurol 2013;74(2):297-300.
PMID 23913475
-
51
-
Pichiecchio A, Veggiotti P, Cardinali S, Longaretti F, Poloni GU, Uggetti C. Lafora disease: spectroscopy study correlated with neuropsychological findings. Eur J Paediatr Neurol 2008;12(4):342-7.
PMID 18063398
-
52
-
Ragona F, Canafoglia L, Castellotti B, et al. Early Parkinsonism in a Senegalese girl with Lafora disease. Epileptic Disord 2020;22(2):233-6.
PMID 32301727
-
53
-
Riva A, Orsini A, Scala M, et al. Italian cohort of Lafora disease: clinical features, disease evolution, and genotype-phenotype correlations. J Neurol Sci 2021;424:117409.**
PMID 33773408
-
54
-
Robitaille Y, Carpenter S, Karpati G, DiMauro S. A distinct form of adult polyglucosan body disease with massive involvement of central and peripheral neuronal processes and astrocytes: a report of four cases and a review of the occurrence of polyglucosan bodies in other conditions such as Lafora's disease and normal aging. Brain 1980;103:315-36.
PMID 6249438
-
55
-
Salar S, Yeni N, Gunduz A, et al. Four novel and two recurrent NHLRC1 (EPM2B) and EPM2A gene mutations leading to Lafora disease in six Turkish families. Epilepsy Res 2012;98:273-6.
PMID 22047982
-
56
-
Serratosa JM, Gomez-Garre P, Gallardo ME, et al. A novel protein tyrosine phosphatase gene is mutated in progressive myoclonus epilepsy of the Lafora type (EPM2). Hum Mol Genet 1999;8(2):345-52.
PMID 9931343
-
57
-
Shahwan A, Farrell M, Delanty N. Progressive myoclonic epilepsies: a review of genetic and therapeutic aspects. Lancet Neurol 2005;4(4):239-48.
PMID 15778103
-
58
-
Singh S, Ganesh S. Lafora progressive myoclonus epilepsy: a meta-analysis of reported mutations in the first decade following the discovery of the EPM2A and NHLRC1 genes. Hum Mutat 2009;30(5):715-23.
PMID 19267391
-
59
-
Singh S, Satishchandra P, Shankar SK, Ganesh S. Lafora disease in the Indian population: EPM2A and NHLRC1 gene mutations and their impact on subcellular localization of laforin and malin. Hum Mutat 2008;29(6):E1-12.
PMID 18311786
-
60
-
Tinuper P, Plazzi G, Monari L, et al. Arylsulfatase A pseudodeficiency and Lafora bodies in a patient with progressive myoclonic epilepsy. Epilepsia 1994;35:332-5.
PMID 7908874
-
61
-
Turnbull J, Kumar S, Ren ZP, et al. Lafora progressive myoclonus epilepsy: disease course homogeneity in a genetic isolate. J Child Neurol 2008;23(2):240-2.
PMID 18263761
-
62
-
Turnbull J, Tiberia E, Striano P, et al. Lafora disease. Epileptic Disord 2016;18(S2):38-62.
PMID 27702709
-
63
-
Turnbull J, Wang P, Girard JM, et al. Glycogen hyperphosphorylation underlies Lafora body formation. Ann Neurol 2010;68(6):925-33.
PMID 21077101
-
64
-
Villanueva V, Alvarez-Linera J, Gomez-Garre P, Gutierrez J, Serratosa JM. MRI volumetry and proton MR spectroscopy of the brain in Lafora disease. Epilepsia 2006;47:788-92.
PMID 16650146
-
65
-
Yamanami S, Ishihara T, Takahashi M, Uchino F. Comparative study of intraneuronal polyglucosan bodies in brains from patients with Lafora disease and aged dogs. Acta Pathol Jpn 1992;42:787-92.
PMID 1335204
-
66
-
Yoshimura I, Kaneko S, Yoshimura N, Murakami T. Long-term observations of two siblings with Lafora disease treated with zonisamide. Epilepsy Res 2001;46:283-7.
PMID 11518630